The Fifth Circuit reinstated in-person dispensing rules for mifepristone on May 1, blocking telehealth and mail access nationwide and triggering emergency Supreme Court appeals.
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit issued a nationwide stay on May 1, 2026, blocking the Food and Drug Administration's post-2023 relaxed dispensing rules for mifepristone and reinstating pre-2023 requirements that patients obtain the drug in person from a certified provider [1]. The ruling effectively bars patients across all 50 states from receiving mifepristone through telehealth prescriptions or mail-order pharmacies, regardless of whether their home state permits or restricts abortion [2].
The case, *Louisiana v. FDA*, centers on a challenge brought by Louisiana and aligned plaintiffs to the FDA's 2023 amendments to the drug's Risk Evaluation and Mitigation Strategy, known as REMS, which had expanded access by permitting retail pharmacy dispensing and remote prescribing [2]. The opinion was authored by Judge Kyle Duncan, a Trump appointee, who wrote that telehealth prescribing of mifepristone injures Louisiana by undermining its laws protecting what the opinion characterized as unborn human life [1]. The panel grounded its holding in the Administrative Procedure Act, concluding the FDA exceeded its statutory authority when it modified the in-person dispensing requirement [2].
The ruling is the first appellate decision to curtail FDA's authority to relax mifepristone's REMS conditions, and its nationwide scope distinguishes it from prior lower-court orders that operated within narrower geographic bounds [2]. Critics of the decision, including the drug's manufacturers, contend the panel's injury analysis stretches state-standing doctrine by allowing Louisiana to assert regulatory injury derived from another sovereign's policy preferences. The opinion also drew attention for language that legal analysts say may signal receptivity on the Fifth Circuit to Comstock Act arguments, a 19th-century federal obscenity statute that some advocates seek to deploy against mail transmission of abortion medication [2].
Danco Laboratories and GenBioPro, the two manufacturers of FDA-approved mifepristone formulations, filed emergency applications with the Supreme Court within days of the ruling, seeking a stay pending further appellate review [1]. The applications place the matter before the justices as the Court's term approaches its final weeks. Depending on how the Supreme Court responds, the stay could either collapse access to telehealth abortion medication within days or be suspended while full merits briefing proceeds. A summary reversal is considered unlikely given the panel's statutory framing, but the Court's prior handling of *FDA v. Alliance for Hippocratic Medicine* in 2024, where it rejected standing for physician plaintiffs, leaves the jurisdictional landscape unsettled [2].
—